Optimi Health produces psilocybin capsules for Phase II MDD study

Optimi Health has completed the production and quality release of a batch of 5mg psilocybin capsules for a Health Canada-authorised Phase II MDD trial and commercial supply to Australia. The psilocybin capsules will be used in a multi-site, open-label study involving up to 200 participants. Credit: BlurryMe / Shutterstock.com. Optimi Health has completed the production and quality release of a batch of 5mg psilocybin capsules for a Health Canada-authorised Phase II major depressive disorder (MDD) trial and commercial supply to Australia. The naturally derived capsules were manufactured at the company’s current good manufacturing practice (cGMP) facility in Princeton, British Columbia,…

Source: Clinical Trials Arena